Rothman N, Hayes R B, Bi W, Caporaso N, Broly F, Woosley R L, Yin S, Feng P, You X, Meyer U A
Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, MD 20892.
Pharmacogenetics. 1993 Oct;3(5):250-5. doi: 10.1097/00008571-199310000-00004.
Eighty-four healthy Chinese male control subjects derived from an occupation-based case-control study of bladder cancer were evaluated for hepatic N-acetyltransferase activity by dapsone and for NAT2 genotype using allele-specific amplification of peripheral leukocyte DNA by the polymerase chain reaction. Fifty-nine percent of the overall variation in acetylation activity was explained by genotype (p < 0.0001). The remaining variation in acetylation was not associated with dapsone N-hydroxylation activity, age, current smoking status, or weight in the study population, or within any genotype subgroup. Although acetylation activity in the homozygous mutant group did not overlap with the other genotype categories, there was moderate overlap in acetylation between the heterozygous mutant and wildtype groups, and substantial variation in acetylation within them. Considering all subjects with the identical NAT2 genotype as phenotypically similar and all subjects with differing NAT2 genotypes as phenotypically distinct may result in misclassification of metabolic risk factors in epidemiological investigations. As such, it would seem prudent, where possible, to collect both acetylation phenotype and NAT2 genotype data, since the advantages and limitations of these two sources of information complement, and serve to assess the accuracy of each other.
从一项基于职业的膀胱癌病例对照研究中选取了84名健康中国男性作为对照受试者,通过氨苯砜评估其肝脏N-乙酰基转移酶活性,并使用聚合酶链反应对外周血白细胞DNA进行等位基因特异性扩增来检测NAT2基因型。基因型解释了乙酰化活性中59%的总体变异(p<0.0001)。在研究人群中,或在任何基因型亚组内,乙酰化的其余变异与氨苯砜N-羟基化活性、年龄、当前吸烟状况或体重均无关联。虽然纯合突变组的乙酰化活性与其他基因型类别没有重叠,但杂合突变组和野生型组之间的乙酰化存在适度重叠,且它们内部的乙酰化存在很大差异。在流行病学调查中,将所有具有相同NAT2基因型的受试者视为表型相似,而将所有具有不同NAT2基因型的受试者视为表型不同,可能会导致代谢风险因素的错误分类。因此,在可能的情况下,收集乙酰化表型和NAT2基因型数据似乎是谨慎的做法,因为这两种信息来源的优点和局限性相互补充,有助于评估彼此的准确性。